https://it.marketscreener.com/quotazioni/azione/REMEGEN-CO-LTD-119080101/attualita/RemeGen-Co-Ltd-presentera-i-risultati-dello-studio-clinico-di-fase-III-su-telitacicept-per-i-pazi-45364078/?utm_source=telegram&utm_medium=social&utm_campaign=share